Clinic Roundup
InSite Vision Inc., of Alameda, Calif., said it started enrollment in the first Phase III trial of BromSite (ISV-303) for the reduction of pain and inflammation after cataract surgery.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.